Skip to main content

Table 3 Metabolic syndrome prevalence according to ATP III and IDF criteria in the total of patients and by gender and presence of clinical lipodystrophy

From: Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients

MS Criteria

Total of patients

Without CL

With CL

P

ATP III [n, (%)]

    

   Total

180 (52.2%)

71 (51.1%)

109 (52.9%)

0.738

   Men

130 (54.4%)

46 (54.1%)

84 (54.5%)

0.949

   Women

50 (47.2%)

25 (46.3%)

25 (48.1%)

0.854

IDF [n, (%)]

    

   Total

149 (43.2%)

64 (46.0%)

85 (41.3%)

0.379

   Men

88 (36.8%)

36 (42.4%)

52 (33.8%)

0.188

   Women

61 (57.5%)

28 (51.9%)

33 (63.5%)

0.227

  1. Note - CL = Clinical lipodystrophy MS = Metabolic syndrome; ATPIII = Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF = International Diabetes Federation; BMI = body mass index.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us